HTB South

PMTCT and maternal health

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Dolutegravir pharmacokinetics in pregnancy

Option B+ Malawi

Adverse pregnancy outcomes and risk factors in the PROMISE trial

PrEP in pregnancy does not increase poor birth outcomes

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Experts disagree with controversial BMJ support for older HIV drugs in pregnancy

Pregnancy common in ART trials in sub-Saharan Africa despite exclusion criteria

Featured HIV and Pregnancy – Swahili translation (January 2018)

Dolutegravir use in pregnancy: results from small Belgian cohort

BHIVA challenges BMJ recommendations on ART during pregnancy: tenofovir still strongly recommend

Featured Experts disagree with controversial BMJ support for older HIV drugs in pregnancy

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

High death rates among HIV positive women postpartum accessing ARVs

Raltegravir in HIV-exposed neonates

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

Modelling data might support use of low dose 400 mg efavirenz in pregnancy

Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

Dolutegravir use in a London cohort – including nine pregnant women

HIV positive and HIV negative pregnancies in the UK and Ireland have similar outcomes including for older women: impressive 15-year review

Featured Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Drug resistance in children after PMTCT and early treatment

Reasons for loss to follow up in the Malawi Option B+ programme

Raltegravir pharmacokinetics in pregnancy and neonates

Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection

Pregnancy outcomes in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

High rates of pregnancy in HIV positive women in Zambia and South Africa

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Data from two cases of rilpivirine use in pregnancy

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Vertical transmission continues to decline in UK and Ireland

Decline in late preterm delivery with vaginal birth in Europe

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Lopinavir/ritonavir in pregnancy: results from a systematic review

Possible mechanisms for adverse pregnancy outcomes in HIV positive women

The challenge of adherence during pregnancy and after

Tenofovir prophylaxis for neonates

Dolutegravir studies continue to show promise

Darunavir use during pregnancy

Management of HIV infection in pregnant women (BHIVA 2012)

Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks

Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes

Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates

Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana

Efavirenz in pregnancy: update of systemic review and meta-analysis

AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme

Increased risk of HIV transmission to HIV-negative partners during pregnancy

Post navigation